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Zeb2 is a negative regulator of 
midbrain dopaminergic axon 
growth and target innervation
Shane V. Hegarty  1, Sean L. Wyatt2, Laura Howard2, Elke Stappers3,4, Danny Huylebroeck  3,4, 
Aideen M. Sullivan1,5 & Gerard W. O’Keeffe 1,5,6
Neural connectivity requires neuronal differentiation, axon growth, and precise target innervation. 
Midbrain dopaminergic neurons project via the nigrostriatal pathway to the striatum to regulate 
voluntary movement. While the specification and differentiation of these neurons have been 
extensively studied, the molecular mechanisms that regulate midbrain dopaminergic axon growth and 
target innervation are less clear. Here we show that the transcription factor Zeb2 cell-autonomously 
represses Smad signalling to limit midbrain dopaminergic axon growth and target innervation. 
Zeb2 levels are downregulated in the embryonic rodent midbrain during the period of dopaminergic 
axon growth, when BMP pathway components are upregulated. Experimental knockdown of Zeb2 
leads to an increase in BMP-Smad-dependent axon growth. Consequently there is dopaminergic 
hyperinnervation of the striatum, without an increase in the numbers of midbrain dopaminergic 
neurons, in conditional Zeb2 (Nestin-Cre based) knockout mice. Therefore, these findings reveal a new 
mechanism for the regulation of midbrain dopaminergic axon growth during central nervous system 
development.
The establishment of neural pathways in the developing central nervous system (CNS) requires coordinated regu-
lation of neuronal differentiation, axon growth and target innervation1. The signals that guide catecholaminergic 
innervation have been intensively studied in the peripheral nervous system (PNS), where the neurotrophic theory 
states that limiting amounts of target-derived neurotrophic factors maintain the survival of the required numbers 
of neurons, and promote the growth of innervating axons in their targets2, 3. More recently, it has emerged that 
cell-autonomous signalling operates in these neurons to regulate axon growth and target innervation4–6. In the 
CNS, most catecholaminergic neurons are found in the brainstem, of which one of the largest populations are the 
midbrain dopaminergic (mDA) neurons of the substantia nigra that project axons to the striatum. Nigrostriatal 
mDA neurons are generated between embryonic day (E) 10 and E12 in mice (E12-E14 in rat)7. mDA axons 
extend rostrally from E11, reach the striatum at E12, and innervate the rostral part of striatum by E16 in mice 
(E18 in rat)8. Naturally-occurring cell death occurs in the postnatal period (~P0-P20) to prune the initially over-
produced nigrostriatal mDA neurons, and depends on target-derived neurotrophic factors such as GDNF9–11. 
The nigrostriatal pathway is crucial for voluntary motor control12, as highlighted by the progressive loss of striatal 
mDA innervation in Parkinson’s disease (PD)13. While the molecular basis of mDA specification and differentia-
tion has been extensively characterised7, it remains largely unknown whether cell-autonomous mechanisms play 
a role in regulating axon growth and target innervation of mDA neurons in the CNS.
From a PCR screen to identify new regulators of mDA axon growth and innervation, we detected the 
expression of Zinc finger E-box-binding homeobox 2 (Zeb2) mRNA in the midbrain during the period of stri-
atal innervation. Zeb2 (Smad-interacting protein-1; Sip1; and Zfhx1b) was identified as a DNA-binding tran-
scriptional repressor that interacts with activated Smad114, a mediator of bone morphogenetic protein (BMP) 
signalling. Within the embryonic CNS, Zeb2 controls hippocampal neuron development and is crucial for the 
correct timing of neurogenesis and gliogenesis in the neocortex in a non-cell-autonomous manner15, 16. Zeb2 also 
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acts cell-autonomously to control: guided migration of cortical GABAergic interneurons17, 18; neocortical axon 
growth19; myelinogenesis in the CNS20; and (re)myelination in the PNS21, 22. In humans, mutations in one ZEB2 
allele causes Mowat-Wilson syndrome (MOWS, OMIM#235730), which includes severe neurodevelopmental 
defects23, 24. Here we investigate for the first time the role of Zeb2 in developing mDA neurons. We describe a new 
function for Zeb2 as a negative regulator of mDA axon growth and target innervation.
Results
Temporal-regulation of Zeb2 expression, and of BMP pathway components, in developing mid-
brain in vivo. Quantification of mRNA levels in the mouse ventral midbrain (VM) at intervals throughout 
the period of initial mDA axon growth and striatal innervation revealed significant differences in Zeb2 expression 
during development. Post-hoc testing showed that Zeb2 mRNA levels significantly increase from E10 to peak at 
E12, followed by a sharp decrease from E12 to E18 (p < 0.0001; Fig. 1A). Because Zeb2 represses BMP signalling 
during nervous system development25, we next investigated the expression of genes encoding components of the 
BMP pathway, which are subject to synexpression, autoregulation and feed-forward/-back regulation14, 25–27. We 
hypothesised that Zeb2 downregulation may be paralleled by modulated expression of some of these BMP path-
way components. To test this, we quantified transcript levels of Gdf5, Bmp2, Bmpr1b and Sizn1 over the same time 
range. Significant age-dependent changes in expression were observed for Gdf5, Bmp2, Bmpr1b and Sizn1 (which 
Figure 1. Temporal regulation of Zeb2 expression in the developing midbrain. (A to E) RT-qPCR of mRNA 
levels of (A) Zeb2 (B) Gdf5, (C) Bmp2, (D) Bmpr1b and (E) Sizn1 in the mouse midbrain from E11 to P1 relative 
to the levels of the geometric mean of three reference mRNAs Gapdh, Sdha and Hprt1. (F) In situ hybridisation 
of Zeb2 and TH mRNA in sagittal sections of the E11.5 mouse VM (indicated by arrow) (©Allen Developing 
Mouse Brain Atlas, 2012). (G) Western blots of mouse midbrain protein extracts showing Zeb2 and BMPR1b 
protein levels at E12 and E16. (H) Quantification of Zeb2 and (I) BMPR1b protein levels in the mouse midbrain 
at E12 and E16. βIII tubulin was used as a loading control. (J) Immunohistochemistry showing p-Smad1/5 (red) 
co-localising with TH (green) in the E14 rat VM (indicated by arrow). (number of repetitions (N) = 3–6 from 
separate litters; mean ± SEM) (*p < 0.05, **p < 0.01, ***p < 0.001; E12 v E16 or E18; t-test or ANOVA with 
post hoc Tukey’s test). Scale bar as indicated.
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encodes a transcriptional co-activator downstream of BMP signalling). These displayed different profiles to that 
of Zeb2, significantly increasing from E12 to E18/P1 (p < 0.05; Fig. 1B to E). Such changes in Zeb2 and Bmpr1b 
mRNA expression were also observed in the rat VM between E14 and E18 (data not shown and28). In situ hybrid-
isation confirmed the quantitative real-time PCR (RT-qPCR) data, and showed localisation of Zeb2 transcripts in 
the E11.5 mouse VM (Fig. 1F). Moreover, western blot was also used to demonstrate that Zeb2 and BMPR1b pro-
tein levels display these age-dependent expression changes in the mouse VM between E12 and E16 (Fig. 1G to I). 
Finally, immunohistochemistry was used to examine phospho-Smad1/5 signalling in the VM at the time of mDA 
axogenesis. Triple_labelled preparations in which mDA neurons were identified by tyrosine hydroxylase (TH) 
staining revealed that p-Smad1/5 were present in, but not limited to, mDA neurons in the E14 rat VM (Fig. 1J). 
This indicates that BMP-Smad signalling is active during mDA axonal growth in the developing midbrain.
Zeb2 is a cell-autonomous negative regulator of BMP-Smad1/5 signalling in cultured mid-
brain neurons. To determine if Zeb2 functions as a repressor of p-Smad1/5 signalling in primary VM neu-
rons, we co-transfected E14 rat VM cells with a green fluorescent protein (GFP)-vector and either a control or 
Zeb2 expression vector. The latter resulted in increased Zeb2 expression in transfected (GFP+) cells (p < 0.001; 
Fig. 2A). Upon vector-encoded Zeb2 overexpression, p-Smad1/5 levels in E14 VM cells were significantly reduced 
at 24 hour (h) post-transfection (p < 0.001; Fig. 2B). We also used SH-SY5Y cells, which are often used to model 
DA neurons and in which BMP-Smad signalling promotes neurite growth29, 30, and found that Zeb2 overexpres-
sion reduced p-Smad1/5 levels (Fig. 2C).
We next transfected both cell types with scrambled or Zeb2-targeting siRNA, and found that knockdown of Zeb2 
resulted in a significant increase in p-Smad1/5 levels in both SH-SY5Y and E14 VM cells (p < 0.05; Fig. 2D to F). 
Zeb2 knockdown increased p-Smad1/5 levels to levels comparable to those in cultures treated with 100 ng/
ml growth differentiation factor 5 (GDF5/BMP14), which was used as a positive control. To determine if this 
upregulation of p-Smad1/5 levels altered Smad-dependent transcription, SH-SY5Y cells were co-transfected 
with a reporter plasmid in which GFP expression is driven by a promoter containing Smad-binding elements 
(SBE-GFP)28, 31, together with either scrambled or Zeb2-siRNA. Control cultures were transfected with the 
SBE-GFP reporter vector, and treated without or with GDF5, the latter resulting in p-Smad-dependent reporter 
transcription. Zeb2 knockdown also led to a significant increase in Smad-dependent transcription (indicated by 
GFP expression) at 48 h (p < 0.01; Fig. 2G and F). These data show that Zeb2 is a negative regulator of p-Smad1/5 
signalling in VM cells, and suggest that decreased Zeb2 expression may facilitate Smad-promoted axon growth.
Zeb2 downregulation is necessary and sufficient for Smad-promoted neurite growth. To 
test this hypothesis, SH-SY5Y cells and E14 VM neurons were co-transfected with a GFP-vector and either a 
scrambled or Zeb2-siRNA, or treated with 100 ng/ml GDF5, and neurite growth was examined 72 h later. 
Knockdown of Zeb2 resulted in a significant increase in neurite growth in both cell types (p < 0.001; Fig. 3A to C). 
This increase in neurite growth was entirely prevented by Smad4 knockdown (Fig. 3A and B), which inhib-
its p-Smad-dependent transcriptional activity28, 29. To identify mDA neurons in GFP-transfected E14 VM cul-
tures, cells were immunocytochemically stained for TH (Fig. 3D). Knockdown of Zeb2 resulted in a significant 
increase in neurite length in TH + (and GFP + ) mDA neurons at 72 h (p < 0.01; Fig. 3E and F). In contrast, 
vector-overexpressed Zeb2 did not affect basal levels of neurite growth in E14 VM neurons, whereas it com-
pletely prevented GDF5-promoted neurite growth (p < 0.05; Fig. 3G). We next examined whether Zeb2 mod-
ulates GDNF-induced neurite growth of E14 VM neurons, and found that Zeb2 overexpression did not inhibit 
the growth-promoting effects of GDNF (data not shown). These results demonstrate that high levels of Zeb2 
maximally repress BMP-Smad-induced neurite growth. They also show that Zeb2 represses p-Smad1/5 activity in 
the basal state below a neurite growth-promoting threshold, and that downregulation of Zeb2 expression in mDA 
neurons facilitates Smad-promoted neurite growth.
BMPR signalling is necessary for axon growth induced by Zeb2 downregulation. We next deter-
mined whether the neurite growth promoted by Zeb2 downregulation involves extracellular and/or intracellular 
mechanisms. As the increase in neurite growth that occurred following RNAi-based knockdown of endogenous 
Zeb2, required Smad4 (Fig. 3A and B), we focused on the canonical BMP-Smad signalling pathway. E14 VM 
neurons were co-transfected with a GFP vector and either a scrambled or Zeb2-siRNA, and then cultured with 
or without noggin (a secreted BMP antagonist) or dorsomorphin (a BMP receptor (BMPR) type 1 inhibitor) for 
72 h (Fig. 3H). While knockdown of Zeb2 promoted a significant increase in neurite length (p < 0.01), noggin 
or dorsomorphin-mediated inhibition of BMPR activation significantly inhibited Zeb2-siRNA-induced neur-
ite growth (Fig. 3I). We subsequently tested whether BMPR1b was required for neurite growth following Zeb2 
downregulation by transfecting Zeb2-siRNA-treated VM cells with BMPR1b-siRNA28, 29, and found that this com-
pletely prevented neurite growth (p < 0.05; Fig. 3J).
We hypothesised that if the mechanism involved in Zeb2-mediated repression of p-Smad-dependent neu-
rite growth occurs at the transcriptional level, then knockdown of a key transcriptional co-factor and binding 
partner of Zeb2 may also increase neurite length. To investigate this, we used STRING analysis to identify the 
top predicted functional binding partner of Zeb2, which was C-terminal binding protein 1 (CtBP1) (Fig. 3J)26, 32. 
Knockdown of CtBP1 in E14 VM neurons had the same neurite growth-promoting effect as knockdown of Zeb2 
(p < 0.001; Fig. 3L), an effect also observed in SH-SY5Y cells (data not shown). This suggests that a Zeb2-CtBP 
transcriptional repressor complex acts to inhibit mDA axonal growth. Interestingly, treatment with noggin or 
dorsomorphin (Fig. 3I), or knockdown of Smad1, Smad5, or Smad7 (an inhibitory Smad that negatively regulates 
BMP-Smad signalling) (Fig. 3L), had no effect on neurite length. This further supports the conclusion that basal 
levels of Zeb2 repress p-Smad signalling below a growth-promoting threshold. Taking these findings together, 
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Figure 2. Zeb2 regulates p-Smad1/5 levels and p-Smad-dependent transcription. (A) Primary cultures of 
E14 rat VM neurons, transfected with a GFP expression vector and either a Zeb2 or control (Cont) expression 
vector, confirmed by immunocytochemistry with densitometry in GFP + cells at 24 h. (B, C) p-Smad1/5 levels 
as determined by (B) immunocytochemistry and (C) western blots in SH-SY5Y cells, and with densitometry in 
GFP+ E14 VM rat neurons 24 h after transfection with control or Zeb2 expression vector (B). (D, E) p-Smad1/5 
levels as determined by (D) western blots in SH-SY5Y and (E) E14 rat VM cultures 48 h after transfection 
with control siRNA or Zeb2-targeting siRNA, or treated with 100 ng/ml GDF5. β-actin was used as a loading 
control. (F) Representative photomicrographs of p-Smad1/5 levels in cells treated with GDF5 or transfected 
with Zeb2 siRNA at 48 h. (G) Graph and (H) representative photomicrographs of the relative levels of SBE-
GFP fluorescence in SH-SY5Y cells transfected with a SBE-GFP reporter vector with either a control siRNA or 
Zeb2-siRNA, or treated with 100 ng/ml GDF5 for 24 h. All data are mean + SEM. (n = 3; *P < 0.05, **P < 0.01, 
***P < 0.001 vs. control; t-test or ANOVA with post hoc Tukey’s test). Scale bar as indicated.
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Zeb2 appears to regulate mDA neuronal growth through a BMPR-Smad1/5 dependent mechanism, raising the 
possibility that Zeb2 may also act to control the extent of target innervation in vivo.
Zeb2 knockout mice have dopaminergic hyperinnervation of the developing striatum. To assess 
the physiological relevance of Zeb2 in mDA axon growth in vivo, we quantified the numbers of mDA neurons, 
and DA innervation density of the developing striatum, in conditional Zeb2-deficient mice (Nestin-Cre:Zeb2fl/KO; 
Zeb2 cKO), and in mice previously demonstrated to produce normal levels of Zeb2 (Nestin-Cre:Zeb2fl/WT; con-
trol)16. There were no significant differences in the numbers of TH+ mDA neurons between the groups at E12.5 
(Fig. 4A and B) or E16.5 (Fig. 4C and D). In the mouse, mDA axons extend from E11, reach striatum from E12 
and innervate the rostral part of striatum by E16 (for review, see7). Therefore, we assessed striatal mDA innerva-
tion density by quantifying TH+ fibres in the striatum at E16.5, a stage at which mDA innervation of the striatum 
is well underway. TH+ innervation density in the striatum of E16.5 Zeb2 cKO was significantly greater than in 
controls (p < 0.01; Fig. 4E and F). To rule out the possibility that this increase in TH+ innervation density was due 
to increased TH expression, rather than increased DA innervation, we analysed the expression of TH following 
Zeb2 knockdown in vitro and in vivo. We found no differences in TH expression in mDA neurons following Zeb2 
Figure 3. Zeb2 is an endogenous negative regulator of Smad-dependent neurite growth. (A,B) Graphs of 
neurite length relative to control in cultures of (A) SH-SY5Y and (B) E14 VM neurons transfected with Zeb2-
siRNA or a control siRNA with or without a Smad4-siRNA and cultured for 72 h. Cells were treated with 100 
ng/ml GDF5 as a positive control. (C, D) Photomicrographs of (C) GFP + neurons and (D) mDA neurons 
(TH + /GFP + ) in cultures of E14 rat VM neurons transfected with Zeb2-siRNA or a control siRNA at 72 h. 
(E) Reconstructed mDA neurons and (F) relative neurite length of mDA neurons from the experiment 
outlined in (D). (G) Graph of relative neurite length in cultures of E14 VM neurons transfected with Zeb2 or 
control expression vectors cultured with or without 100 ng/ml GDF5 for 72 h. (H) Schematic of experimental 
approaches. (I,J) Graph of neurite length in cultures of E14 VM neurons transfected with Zeb2-siRNA or a 
control siRNA and cultured with noggin or dorsomorphin (I) or a control siRNA and BMPR1b-siRNA (J), after 
72 h. (K) STRING score showing the two functional binding partners of Zeb2. (L) Graph of neurite length in 
cultures of E14 VM neurons transfected with control siRNA or Smad1, Smad5, Smad7, Zeb2 or CtBP1 siRNA 
and cultured for 72 h. (n = 3; *P < 0.05, **P < 0.01, ****P < 0.0001 vs. control; t-test or ANOVA with post hoc 
Tukey’s test; # P < 0.05; ### P < 0.001). All data are the mean + SEM. Scale bar = 100 µm.
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knockdown (data not shown). These findings suggest that Zeb2 plays a physiological role in regulating mDA axon 
growth and target innervation in vivo.
Discussion
We report that Zeb2 is a novel negative regulator of mDA axon growth and target innervation during embryogen-
esis (Fig. 5). Downregulation of Zeb2 expression in embryonic VM neurons resulted in promotion of axon growth 
via Smad signalling, while its absence in Zeb2-deficient mice led to mDA striatal hyperinnervation. In the mouse 
VM, Zeb2 expression increased from E10 to sharply peak at E12, suggesting that Zeb2 may contribute to mDA 
neurogenesis33, as it does in the hippocampal anlage and the embryonic neocortex15, 16. However, no changes in 
numbers of TH+ mDA neurons were observed in the Zeb2 cKO mice at E12.5 or E16.5. Interestingly, Wnt5a is 
expressed in the mouse VM at E11.5 and is important for the initiation of neurite outgrowth, but by E14.5 causes 
neurite retraction34. Zeb2 has been identified as a candidate downregulator (either directly or indirectly) of Sfrp1, 
which encodes a secreted Wnt antagonist15, 33. Thus, high levels of Zeb2 at E12 may facilitate Wnt-promoted initi-
ation of mDA axon growth, which may then become more responsive to BMP-Smad signalling-induction as Zeb2 
expression declines from E12-E18, due to a combination of increasing inhibition of Wnt signalling (via increased 
Sfrp1) and decreasing Zeb2-mediated inhibition of BMP-Smad signalling. Indeed, axonal growth requires inte-
gration of multiple signals, as well as the changing of responses to cues along their trajectory to targets1. This 
proposed mechanism is supported by our finding that Zeb2 negatively regulates BMP-Smad dependent gene 
transcription, in agreement with other studies14, 20, 25. Moreover, Zeb2 regulates Wnt and BMP signalling output 
Figure 4. Zeb2-deficient mice have dopaminergic hyperinnervation of the striatum. (A,C) Graph of mDA 
neuron number in Zeb2 cKO mice and mice expressing normal levels of Zeb2 (control) at (A) E12.5 and (C) 
E16.5. (B, D) Representative sections of the midbrain Zeb2 cKO and control mice at (B) E12.5 and (D) E16.5 
showing DAPI (blue), GFP (green) and TH (red). (E) Graph of TH + striatal innervation density at E16.5 in 
Zeb2 cKO and Control mice. (F) Representative TH-stained coronal sections through the striatum of Zeb2 
cKO and control mice at E16.5. The representative serial sections were taken at positions 160 µm and 280 µm 
through the striatum respectively (left hemispheres shown). (n = 5; **p < 0.01 vs. control; t-test). All data are 
the mean + SEM. Scale bar = 100 µm.
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during neural crest development, via a mechanism that may depend on Smads25, 35. In addition to this, TGF-β 
superfamily members, such as GDNF and TGF-βs, are expressed during nigrostriatal pathway development and 
regulate its development9–11, 36–38. While we found that Zeb2 did not inhibit the neurite growth-promoting effects 
of GDNF in vitro, it would be interesting in future work to disentangle any potential cross-talk between Zeb2 and 
other molecular pathways that promote neurite growth in mDA neurons, such TGF-βs and Wnts.
Downregulation of Zeb2 also facilitated axon growth through a BMP-BMPR-Smad mechanism. In support 
of this, canonical BMP-BMPR1b-Smad signalling induces mDA neuronal growth28. Furthermore, we found that 
increased Zeb2 levels represses GDF5-promoted, BMPR-Smad-mediated neurite growth. Our findings also sug-
gest that such repression by Zeb2 is dependent on the CtBP co-repressor, similar to Zeb2-mediated neural induc-
tion in the amphibian embryo26. These data indicate that downregulation of Zeb2 during mDA axonal growth 
and target innervation may facilitate BMP-Smad-mediated induction of this developmental process. In support 
of this, BMPs and BMPRs are present in both the midbrain and striatum, as well as in mDA neurons, at key 
time-points for nigrostriatal pathway development28, 36. Thus, BMPs may act locally in the midbrain, and/or in the 
striatum as target-derived neurotrophic factors, to induce mDA axonal growth and target innervation in a process 
that, at least in part, is negatively regulated by Zeb2 levels in a cell autonmous manner. Indeed, axon growth and 
target innervation of peripheral catecholaminergic neurons is controlled by cell-autonomous signalling4–6, and is 
also regulated by Wnt5a and BMP-Smad signalling6, 31. In future studies, it will be important to further character-
ise the role of BMP ligands in mDA innervation, and to determine whether Zeb2 functions in a similar manner 
in peripheral catecholaminergic neurons.
We also report for the first time mDA hyperinnervation of the striatum in the Zeb2 cKO mouse embryos at 
E16.5. This may recapitulate some developmental defects in MOWS, in particular the enlarged basal ganglia24. 
However, whether this mDA hyperinnervation persists throughout the lifespan is an important topic for future 
investigation. Nigrostriatal mDA neurons are initially overproduced during neurogenesis, and subsequently 
undergo naturally-occurring cell death in the postnatal period (~P0-P20)9. Future studies should analyse striatal 
mDA fibre density and mDA neuronal number in the Zeb2 cKO mouse at ages following this period of postna-
tal developmental programmed cell death. Finally, progressive degeneration of striatal mDA innervation causes 
debilitating motor dysfunctions in PD13. There is robust evidence that mDA axonal degeneration in the striatum 
occurs early in PD pathogenesis, and precedes neuronal loss39, 40. Thus, transcription factors that control mDA 
axon growth may be novel candidate targets in future therapeutic approaches for PD41. In this regard, the present 
study suggests that Zeb2 downregulation may be a viable neurotrophic strategy to restore striatal mDA inner-
vation for the treatment of PD. In summary, our work provides new evidence for a Zeb2-controlled signalling 
mechanism that operates in central catecholaminergic neurons to regulate axon growth and appropriate target 
innervation during embryonic development.
Figure 5. Zeb2 cell-autonomously represses Smad signalling to limit mDA neuronal growth and target 
innervation. (A) Schema showing the proposed role for Zeb2 as a cell-autonomous regulator of BMP-Smad1/5 
signalling, which promotes neurite growth in mDA neurons. In future work it will be interesting to disentangle 
any potential cross-talk between Zeb2 and other molecular pathways that promote neurite growth in mDA 
neurons, including TGF-βs and Wnts. (B) Proposed model of the contribution of Zeb2 to the embryonic 
development of mDA target innervation based on current data. During peak mDA neurogenesis at ~E12 in 
mice, high levels of Zeb2 repress BMP-Smad signalling to limit mDA neurite growth. As mDA neurons extend 
axons and innervate the striatum from E12-E16, a reduction in Zeb2 levels leads to an increase in BMP-Smad-
dependent transcriptional activity which promotes neurite growth in mDA neurons. (C) Knockdown of Zeb2 
removes a cell-autonomous inhibitory mechanism that results in excessive mDA neurite growth through 
BMPR1b-Smad-dependent signalling, which causes hyperinnervation of the striatum in vivo. Whether this 
mDA hyperinnervation persists throughout the lifespan is an important topic for future investigation. In 
summary, these data provide new evidence for a Zeb2-controlled signalling mechanism that operates in mDA 
neurons to regulate axon growth and target innervation during embryonic CNS development.
www.nature.com/scientificreports/
8SCIENtIfIC RepoRts | 7: 8568  | DOI:10.1038/s41598-017-08900-3
Methods
Cell Culture. All experiments were carried out in accordance with relevant guidelines and regulations, in 
compliance with law, and approved by the UCC Animal Ethics Experimentation Committee and the Health 
Products Regulatory Authority. For E14 rat VM cultures, E14 embryos were obtained by laporatomy from time-
mated female Sprague-Dawley rats following decapitation under terminal anaesthesia induced by the inhalation 
of isoflurane (Isoflo®). Dissected VM tissue was centrifuged at 100 g for 5 minutes at room temperature. The 
tissue pellet was then incubated in a 0.1% trypsin-Hank’s Balanced Salt solution for 5 minutes, at 37 °C with 5% 
CO2. Fetal calf serum (FCS; Sigma) was then added to the tissue followed by centrifugation at 100 g for 5 minutes 
at 4 °C. The resulting cell pellet was resuspended in 1 ml of differentiation media (Dulbecco’s modified Eagle’s 
medium/F12, 33 mM D-glucose, 1% L-glutamine, 1% FCS, supplemented with 2% B27; all Sigma) using a P1000 
Gilson pipette, and then carefully triturated using a sterile plugged flame-polished Pasteur pipette, followed by a 
25-gauge needle and syringe. Cell density was estimated using a haemocytometer. Cells were plated on poly-D-
lysine (Sigma)-coated 24-well tissue culture plates at a density of 5 × 104 cells per well in 500 μl of differentiation 
media at 37 °C with 5% CO2.
SH-SY5Y cells (Sigma; passages 18–25) were used as a model of human DA neurons in this study. These were 
maintained in Dulbecco’s Modified Eagle Medium Nutrient Mixture F-12 (Sigma), supplemented with 10% foetal 
calf serum (Sigma), 100 nM L-Glutamine (Sigma), 100 U/ml Penicillin (Sigma), 10 µg/ml Streptomycin (Sigma), 
in a humidified atmosphere containing 5% CO2 at 37 °C.
Where indicated, cells were treated daily with 100 ng/ml of GDF5 (kindly provided by Biopharm GmbH), 
1 μg/ml of dorsomorphin (Sigma) or 200 ng/ml of noggin (R&D Systems).
Electroporation of Cultured Cells. Electroporation of cultured cells was carried out using the NeonTM 
Transfection System (Invitrogen). Cell suspensions were prepared for counting (as outlined above), and the 
required volume of cells to give 200,000 cells per well was centrifuged at 4 °C at 100 g for 5 minutes. The cell pellet 
was washed twice with 10 mM phosphate buffered saline (PBS) (without CaCl2 and MgCl2) (Sigma), and then 
resuspended in the required amount of the manufacturers resuspension buffer (12 µl per transfection/plasmid) 
(Invitrogen). 0.5 µg of GFP plasmid; 1 µg of desired plasmid DNA (Zeb2 overexpression42 or Smad4 siRNA29 
vectors); and/or 500 nM of Zeb2, CtBP1, Smad1, Smad5, or Smad7 siRNA (Life Technologies) was added to the 
resuspended cells. 10 µl of the cell/plasmid mixture was then electroporated according to the manufacturer’s pro-
tocol under specific parameters (1100 V; 30 ms; 2 pulses).
Immunocytochemistry. Cultures were fixed for 10 minutes using 100% ice-cold methanol (E14 VM cells), 
or 4% paraformaldehyde (SH-SY5Y cells). Following 3 washes in 10 mM PBS-T (0.02% Triton X-100 in 10 mM 
PBS) for permeabilization, cultures were incubated in blocking solution (5% bovine serum albumin) for 1 h at 
room temperature. Cultures were subsequently incubated in the following primary antibodies: phopsho-Smad 
1/5 (p-Smad1/5; 1:200; Cell Signalling), TH (1:200; mouse monoclonal; Millipore, or 1:300; rabbit polyclonal; 
Millipore), Zeb2 (1:50; Santa Cruz) and β-actin (1:200; Sigma) diluted in 1% bovine serum albumin in 10 mM 
PBS at 4 °C overnight. Following 3 × 5 minutes washes in PBS-T, cells were incubated in Alexa Fluor 488- and/
or 594-conjugated secondary antibodies (1:500; Invitrogen) reactive to the species of the primary antibodies and 
diluted in 1% bovine serum albumin in 10 mM PBS, at room temperature for 2 h in the dark. Cultures were coun-
terstained with bisbenzimide (1:1000 in 10 mM PBS; Sigma). Negative controls in which the primary antibody 
was omitted were also prepared (not shown). Cells were imaged under an Olympus IX70 inverted microscope 
fitted with an Olympus DP70 camera and AnalysisDTM software. For densitometric analysis, the fluorescence 
intensity of individual cells stained for p-Smad 1/5 was measured using Image J analysis software.
Conditional Zeb2 knockout Mice. All animal experiments were carried out in compliance with law and 
were ethically approved. Mice carrying a floxed (exon 7) Zeb2 allele (Zeb2fl/KO)43 were crossed with Nestin-Cre44 
mice.
Immunohistochemistry. Brains were dissected and washed in ice-cold PBS and fixed overnight with 
4% paraformaldehyde (wt/vol) followed by progressive alcohol-assisted dehydration and paraffin embedding. 
10-μm-thick serial sections were cut on a Leica microtome and then processed for immunohistochemistry using 
an automated platform (Ventana Discovery, Ventana Medical Systems) and mounted in DAPI-supplemented 
Mowiol. The following primary antibodies were used: p-Smad1/5 (1:50), TH (Novocastra; 1:500), and GFP 
(Novocastra; 1:500). For secondary antibodies, CY2-, CY3- or biotin-conjugated donkey antibodies (all at 
1:600, Jackson ImmunoResearch) were used. Sections were photographed using a confocal radiance micro-
scope connected to a spot camera (Visitron Systems) and data analysis was done with ImageJ software. 5 control 
and 5 knockout brains were analyzed, and 10 sections per brain were quantified. In each brain and time point, 
TH-positive cell bodies or TH-positive neurites/fibres were quantified in midbrain/striatum of the same coronal 
plane. TH-positive striatal fibres were analysed through 400 µm of the striatum, spanning from the rostral stria-
tum to the region between the caudal striatum and diencephalon. Brain regions were identified using an atlas of 
the embryonic mouse brain and landmarks, such as the lateral ventricles, after which 10 µm serial sections (1:10 
series) were counted and every fourth section was sampled from the striatum. For the striatal innervation exper-
iments, TH-positive fibres were quantified in the E16.5 mouse striatum using ImageJ.
Quantitative real-time PCR (RT-qPCR). The midbrains of E10 to P1 CD-1 mice, obtained from 
time-mated pregnant dams as outlined above, were micro-dissected and total RNA was then extracted and puri-
fied. Midbrain samples were disrupted and homogenised in 1 ml of QIAzol Lysis Reagent (Qiagen). After the 
addition of 200 µl chloroform, homogenates were separated into aqueous and organic phases by centrifugation at 
10,000 g for 15 minutes. The upper aqueous phase was mixed with an equal volume of 70% ethanol, to precipitate 
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the RNA, and then transferred to an RNeasy Mini spin column placed in a 2 ml collection tube. Total RNA was 
purified using the Qiagen RNeasy Mini extraction kit and RNase-free DNase set, according to the manufacturer’s 
instructions.
The levels of Zeb2, Gdf5, Bmp2, Bmpr1b and Sizn1 mRNAs were quantified by RT-qPCR relative to a geomet-
ric mean of mRNAs for the house keeping enzymes glyceraldehyde phosphate dehydrogenase (Gapdh), succi-
nate dehydrogenase (Sdha) and hypoxanthine phosphoribosyltransferase-1 (Hprt1). 5 μl of total midbrain RNA 
was reverse transcribed for 1 h at 45 °C using the AffinityScript kit (Agilent, Berkshire, UK) in a 25 µl reaction 
according to the manufacturer’s instructions. 2 µl of cDNA was amplified in a 20 µl reaction volume using Brilliant 
III ultrafast qPCR master mix reagents (Agilent Technologies). PCR products were detected using dual-labelled 
(FAM/BHQ1) hybridization probes specific to each of the cDNAs (MWG/Eurofins, Ebersberg, Germany). The 
PCR primers were: Zeb2 forward: 5′-GGT CCA GAA GAA ATG AAG-3′ and reverse: 5′-ATC TCT TTC CTC 
CAG TTT-3′; Gdf5 forward: 5′-TAA TGA ACT CTA TGG ACC-3′ and reverse: 5′-GAT GAA GAG GAT GCT 
AAT-3′; Bmp2 forward: 5′-CGT CAA GCC AAA CAC AAA-3′ and reverse: 5′-ACG ATC CAG TCA TTC CAC-
3′; Bmpr1b forward: 5′-AGT GTA ATA AAG ACC TCC A-3′ and reverse: 5′-AAC TAC AGA CAG TCA CAG-
3′; Sizn1 forward: 5′- ACA ATG AGA GTG ACA AGG-3′ and reverse: 5′-GGT TAA TTT AAG GCT GGG-3′; 
Gapdh forward: 5′-GAG AAA CCT GCC AAG TAT G-3′ and reverse: 5′-GGA GTT GCT GTT GAA GTC-3′; Sdha 
forward: 5′-GGA ACA CTC CAA AAA CAG-3′ and reverse: 5′-CCA CAG CAT CAA ATT CAT-3′; Hprt1 for-
ward: 5′-TTA AGC AGT ACA GCC CCA AAA TG-3′ and reverse: 5′-AAG TCT GGC CTG TAT CCA ACA C-3′. 
Dual-labelled probes were: Zeb2: 5′-FAM-TGG CAA AGT ATT CCT CAA AGT CT-BHQ1-3′; Gdf5: 5′-FAM-TGA 
ATC CAC ACC ACC CAC TTG-BHQ1-3′; Bmp2: 5′-FAM-TCA CTG AAG TCC ACA TAC AAA GGG T-BHQ1-
3′; Bmpr1b: 5′-FAM-CCA CTC TGC CTC CTC TCA AG-BHQ1-3′; Sizn1: 5′-FAM-TCG CAT CTT ACT GTG 
GTT CA-BHQ1-3′; Gapdh: 5′-FAM-AGA CAA CCT GGT CCT CAG TGT-BHQ1-3; Sdha: 5′-FAM-CCT GCG 
GCT TTC ACT TCT CT-BHQ1–3, Hrpt1: 5′-FAM-TCG AGA GGT CCT TTT CAC CAG CAA G-BHQ1–3′. 
Forward and reverse primers were used at a concentration of 150 nM and dual-labelled probes were used at a con-
centration of 300 nM. PCR was performed using the Mx3000 P platform (Agilent) using the following conditions: 
95 °C for 3 minutes followed by 45 cycles of 95 °C for 12 seconds and 60 °C for 35 seconds. Standard curves were 
generated for each cDNA for every real time PCR run, by using serial threefold dilutions of reverse transcribed 
mouse adult brain total RNA (Zyagen, San Diego, USA). Relative mRNA levels were quantified in VMs dissected 
from 3–6 separate animals for each age. Primer and probe sequences were designed using Beacon Designer software 
(Premier Biosoft, Palo Alto, USA).
Analysis of Neuronal Complexity. The total neurite length of individual cultured cells was measured at 
72 h using Sholl analysis as previously described45, 46. Traces of GFP + /TH + neurons were carried out using the 
CorelDRAW × 4 software and analysed as previously described47. Briefly, neurite length (NL) was calculated 
using the following formula; NL = α x T x (π/2), where α is the number of times the neurite intersects the grid 
lines, and T is the distance between the gridlines on the magnified image (taking into account the magnification 
factor). Individual neurons with intact processes were analysed from within 20 random fields (1.6 × 105 µm2) per 
condition, where any neuron with a process that was at least one and half times the length of the soma was deter-
mined as an intact process (which precludes analysis of apoptotic neurons).
Western Blotting. Western blotting was carried out as described48. Cells or freshly dissected embryonic 
mouse VM tissue were lysed in radioimmunoprecipitation assay (RIPA) buffer (50 μl RIPA per 1 × 106 cells or 
5 mg of tissue; 50 mM Tris-HCL; 150 mM NaCl, 1% Triton X-100, 1 mM EDTA, 1 mM NaF, 1 mM Na3VO4, 
1 μg/ml leupeptin and 1 μg/ml pepstatin) for 1 h on ice, and insoluble debris was removed by centrifugation. 
15 μg of protein was run by SDS-PAGE and transferred to nitrocellulose membranes using a Mini Trans-Blot 
Electrophoretic Transfer Cell (Bio-Rad, CA, USA). The membranes were incubated with primary antibodies 
against p-Smad1/5 (1:1000), BMPR1b (1:1000; Abcam); Zeb2 (1:250), βIII tubulin (1:2000; R&D Systems) or 
β-actin (1:2000) overnight at 4 °C, washed, incubated with the appropriate goat IR700/800-labelled secondary 
antibodies (1:10000; Licor), washed and visualised with Odyssey (Licor). Protein levels were normalised to 
β-actin or βIII tubulin by densitometry using Image Studio Lite software (Licor).
Statistical Analysis. Unpaired Student’s t-test or one-way ANOVA with a post hoc Tukey’s test was per-
formed, as appropriate, to determine significant differences between groups. Results were expressed as means 
with SEM and deemed significant when p < 0.05.
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